Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
The GLP-1 agonists drugs market report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Glucagon-like Peptide-1 (GLP-1) Agonists in different geographies, along with insights on Glucagon-like Peptide-1 (GLP-1) Agonists pricing reimbursements to curate the best opportunities and assess the markets potential
Nanofat grafting: basic research and clinical applications
There are no PCOS-specific RCTs for sermorelin, but its relevance to insulin-resistant PCOS as a supportive metabolic intervention is reasonably grounded
